New combo tackles Hard-to-Treat myeloma
NCT ID NCT05646836
First seen Nov 17, 2025 · Last updated Jun 17, 2026 · Updated 19 times
Summary
This early-phase study tests a new drug (XmAb24306) combined with another drug (cevostamab) in people with multiple myeloma that has come back or stopped responding to at least three prior treatments. The main goal is to check safety and find the right dose. About 90 participants will take part, and researchers will also monitor how well the drugs work against the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Alfred Hospital
Melbourne, Victoria, 3004, Australia
-
Asan Medical Center - PPDS
Seoul, 05505, South Korea
-
Clinica Universidad de Navarra
Pamplona, Navarre, 31008, Spain
-
Evangelismos General Hospital of Athens
Athens, 106 76, Greece
-
Hospital Universitari i Politecnic La Fe de Valencia
Valencia, 46026, Spain
-
Oslo University Hospital Rikshospitalet
Oslo, N - 0424, Norway
-
Peter Maccallum Cancer Centre
Melbourne, Victoria, 3000, Australia
-
Rabin Medical Center-Beilinson Campus
Petah Tikva, 4941492, Israel
-
Royal Adelaide Hospital
Adelaide, South Australia, 5000, Australia
-
Severance Hospital, Yonsei University
Seoul, 03722, South Korea
-
Sygehus Lillebaelt - Vejle Sygehus
Vejle, 7100, Denmark
-
Tel Aviv Sourasky Medical Center PPDS
Tel Aviv, 64239, Israel
-
University of Athens, Hematological Clinic,
Athens, 115 28, Greece
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.